25 XP   0   0   10

Allovir Inc
Buy, Hold or Sell?

Let's analyse Allovir together

PenkeI guess you are interested in Allovir Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Allovir Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Allovir Inc

I send you an email if I find something interesting about Allovir Inc.

Quick analysis of Allovir (30 sec.)










What can you expect buying and holding a share of Allovir? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$1.27
Expected worth in 1 year
$0.58
How sure are you?
22.2%

+ What do you gain per year?

Total Gains per Share
$-0.69
Return On Investment
-85.7%

For what price can you sell your share?

Current Price per Share
$0.80
Expected price per share
$0.6425 - $1.34
How sure are you?
50%

1. Valuation of Allovir (5 min.)




Live pricePrice per Share (EOD)

$0.80

Intrinsic Value Per Share

$-12.13 - $-14.14

Total Value Per Share

$-10.86 - $-12.87

2. Growth of Allovir (5 min.)




Is Allovir growing?

Current yearPrevious yearGrowGrow %
How rich?$145.7m$206.8m-$15.9m-8.4%

How much money is Allovir making?

Current yearPrevious yearGrowGrow %
Making money-$47m-$42.1m-$4.9m-10.5%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Allovir (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#310 / 1010

Most Revenue
#917 / 1010

Most Profit
#882 / 1010

Most Efficient
#364 / 1010

What can you expect buying and holding a share of Allovir? (5 min.)

Welcome investor! Allovir's management wants to use your money to grow the business. In return you get a share of Allovir.

What can you expect buying and holding a share of Allovir?

First you should know what it really means to hold a share of Allovir. And how you can make/lose money.

Speculation

The Price per Share of Allovir is $0.8. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Allovir.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Allovir, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.27. Based on the TTM, the Book Value Change Per Share is $-0.17 per quarter. Based on the YOY, the Book Value Change Per Share is $0.00 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Allovir.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.52-65.0%-0.41-51.8%-0.37-45.9%-0.30-37.0%-0.30-37.0%
Usd Book Value Change Per Share-0.43-53.9%-0.17-21.4%0.00-0.2%0.078.8%0.078.8%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.43-53.9%-0.17-21.4%0.00-0.2%0.078.8%0.078.8%
Usd Price Per Share0.68-2.54-5.92-10.05-10.05-
Price to Earnings Ratio-0.33--1.66--4.04--8.84--8.84-
Price-to-Total Gains Ratio-1.58--3.13--11.86--41.55--41.55-
Price to Book Ratio0.54-1.46-3.27-4.05-4.05-
Price-to-Total Gains Ratio-1.58--3.13--11.86--41.55--41.55-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.8
Number of shares1250
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.170.07
Usd Total Gains Per Share-0.170.07
Gains per Quarter (1250 shares)-214.2188.13
Gains per Year (1250 shares)-856.82352.53
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-857-8670353343
20-1714-17240705696
30-2570-2581010581049
40-3427-3438014101402
50-4284-4295017631755
60-5141-5152021152108
70-5998-6009024682461
80-6855-6866028202814
90-7711-7723031733167
100-8568-8580035253520

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.018.00.00.0%0.018.00.00.0%0.018.00.00.0%
Book Value Change Per Share1.03.00.025.0%2.010.00.016.7%4.013.01.022.2%4.013.01.022.2%4.013.01.022.2%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.018.00.0%0.00.018.00.0%0.00.018.00.0%
Total Gains per Share1.03.00.025.0%2.010.00.016.7%4.013.01.022.2%4.013.01.022.2%4.013.01.022.2%

Fundamentals of Allovir

About Allovir Inc

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. The company was incorporated in 2013 and is based in Waltham, Massachusetts.

Fundamental data was last updated by Penke on 2024-04-11 00:21:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Allovir Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Allovir earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Allovir to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Allovir Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-85.0%+85.0%
5Y-85.0%10Y-85.0%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--207.2%+207.2%
TTM--216.8%+216.8%
YOY--282.3%+282.3%
5Y-85.0%-436.8%+351.8%
10Y-85.0%-597.3%+512.3%
1.1.2. Return on Assets

Shows how efficient Allovir is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Allovir to the Biotechnology industry mean.
  • -31.3% Return on Assets means that Allovir generated $-0.31 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Allovir Inc:

  • The MRQ is -31.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -20.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-31.3%TTM-20.3%-11.0%
TTM-20.3%YOY-17.3%-2.9%
TTM-20.3%5Y-13.4%-6.9%
5Y-13.4%10Y-13.4%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-31.3%-13.3%-18.0%
TTM-20.3%-12.8%-7.5%
YOY-17.3%-11.6%-5.7%
5Y-13.4%-13.8%+0.4%
10Y-13.4%-15.6%+2.2%
1.1.3. Return on Equity

Shows how efficient Allovir is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Allovir to the Biotechnology industry mean.
  • -40.9% Return on Equity means Allovir generated $-0.41 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Allovir Inc:

  • The MRQ is -40.9%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -25.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-40.9%TTM-25.9%-15.1%
TTM-25.9%YOY-21.2%-4.7%
TTM-25.9%5Y-15.3%-10.6%
5Y-15.3%10Y-15.3%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-40.9%-16.9%-24.0%
TTM-25.9%-16.1%-9.8%
YOY-21.2%-14.9%-6.3%
5Y-15.3%-19.3%+4.0%
10Y-15.3%-20.1%+4.8%

1.2. Operating Efficiency of Allovir Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Allovir is operating .

  • Measures how much profit Allovir makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Allovir to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Allovir Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-153.5%+153.5%
5Y-153.5%10Y-153.5%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--298.0%+298.0%
TTM--238.5%+238.5%
YOY--288.4%+288.4%
5Y-153.5%-486.2%+332.7%
10Y-153.5%-628.4%+474.9%
1.2.2. Operating Ratio

Measures how efficient Allovir is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Allovir Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y0.989-0.989
5Y0.98910Y0.9890.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.235-3.235
TTM-3.310-3.310
YOY-3.838-3.838
5Y0.9895.679-4.690
10Y0.9897.823-6.834

1.3. Liquidity of Allovir Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Allovir is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 6.61 means the company has $6.61 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Allovir Inc:

  • The MRQ is 6.615. The company is very able to pay all its short-term debts. +2
  • The TTM is 7.512. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ6.615TTM7.512-0.898
TTM7.512YOY10.592-3.080
TTM7.5125Y12.612-5.100
5Y12.61210Y12.6120.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.6153.863+2.752
TTM7.5124.169+3.343
YOY10.5925.337+5.255
5Y12.6126.122+6.490
10Y12.6126.434+6.178
1.3.2. Quick Ratio

Measures if Allovir is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Allovir to the Biotechnology industry mean.
  • A Quick Ratio of 9.80 means the company can pay off $9.80 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Allovir Inc:

  • The MRQ is 9.799. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 10.279. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ9.799TTM10.279-0.480
TTM10.279YOY15.835-5.556
TTM10.2795Y18.230-7.951
5Y18.23010Y18.2300.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ9.7993.504+6.295
TTM10.2793.991+6.288
YOY15.8355.371+10.464
5Y18.2306.088+12.142
10Y18.2306.395+11.835

1.4. Solvency of Allovir Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Allovir assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Allovir to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.24 means that Allovir assets are financed with 23.6% credit (debt) and the remaining percentage (100% - 23.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Allovir Inc:

  • The MRQ is 0.236. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.211. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.236TTM0.211+0.024
TTM0.211YOY0.177+0.035
TTM0.2115Y0.292-0.080
5Y0.29210Y0.2920.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2360.339-0.103
TTM0.2110.337-0.126
YOY0.1770.271-0.094
5Y0.2920.368-0.076
10Y0.2920.388-0.096
1.4.2. Debt to Equity Ratio

Measures if Allovir is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Allovir to the Biotechnology industry mean.
  • A Debt to Equity ratio of 30.9% means that company has $0.31 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Allovir Inc:

  • The MRQ is 0.309. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.269. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.309TTM0.269+0.040
TTM0.269YOY0.216+0.053
TTM0.2695Y0.155+0.114
5Y0.15510Y0.1550.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3090.392-0.083
TTM0.2690.403-0.134
YOY0.2160.335-0.119
5Y0.1550.427-0.272
10Y0.1550.461-0.306

2. Market Valuation of Allovir Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Allovir generates.

  • Above 15 is considered overpriced but always compare Allovir to the Biotechnology industry mean.
  • A PE ratio of -0.33 means the investor is paying $-0.33 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Allovir Inc:

  • The EOD is -0.385. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.327. Based on the earnings, the company is expensive. -2
  • The TTM is -1.657. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.385MRQ-0.327-0.058
MRQ-0.327TTM-1.657+1.329
TTM-1.657YOY-4.044+2.388
TTM-1.6575Y-8.838+7.182
5Y-8.83810Y-8.8380.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.385-2.300+1.915
MRQ-0.327-2.656+2.329
TTM-1.657-2.718+1.061
YOY-4.044-4.145+0.101
5Y-8.838-6.258-2.580
10Y-8.838-6.315-2.523
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Allovir Inc:

  • The EOD is -0.747. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.635. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.387. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.747MRQ-0.635-0.112
MRQ-0.635TTM-2.387+1.752
TTM-2.387YOY-4.795+2.408
TTM-2.3875Y-12.127+9.740
5Y-12.12710Y-12.1270.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.747-2.974+2.227
MRQ-0.635-3.306+2.671
TTM-2.387-3.508+1.121
YOY-4.795-5.613+0.818
5Y-12.127-8.378-3.749
10Y-12.127-8.873-3.254
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Allovir is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.54 means the investor is paying $0.54 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Allovir Inc:

  • The EOD is 0.630. Based on the equity, the company is cheap. +2
  • The MRQ is 0.536. Based on the equity, the company is cheap. +2
  • The TTM is 1.461. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD0.630MRQ0.536+0.095
MRQ0.536TTM1.461-0.925
TTM1.461YOY3.270-1.810
TTM1.4615Y4.049-2.588
5Y4.04910Y4.0490.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.6301.914-1.284
MRQ0.5362.116-1.580
TTM1.4612.097-0.636
YOY3.2702.881+0.389
5Y4.0493.550+0.499
10Y4.0493.936+0.113
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Allovir Inc.

3.1. Institutions holding Allovir Inc

Institutions are holding 46.257% of the shares of Allovir Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Artal Group S A5.78380.1491659716700
2023-12-31FMR Inc4.99090.00035692782-3989678-41.2052
2023-12-31Millennium Management LLC3.42270.001239040093160593425.1446
2023-12-31Wasatch Advisors Inc.3.3180.01423784623-2535248-40.1155
2023-12-31BlackRock Inc3.09140.00013526112-319514-8.3085
2023-12-31Vanguard Group Inc2.5763029386051870796.7991
2023-12-31Woodline Partners LP2.20140.0186251100444433821.5002
2023-09-30Redmile Group, LLC1.67270.1952190796900
2023-12-31Geode Capital Management, LLC1.09870.00011253238739976.275
2023-12-31American International Group Inc1.01190.00321154193-101-0.0087
2023-12-31State Street Corporation0.947801081104-10894-0.9976
2023-12-31Goldman Sachs Group Inc0.81720.0001932142625009203.4978
2023-12-31Renaissance Technologies Corp0.6680.0008761965428243128.3233
2023-12-31Morgan Stanley - Brokerage Accounts0.44930512517-41161-7.4341
2023-12-31Charles Schwab Investment Management Inc0.41720.00014758326305315.2752
2023-12-31Northern Trust Corp0.37630.0001429178-46626-9.7994
2023-12-31JPMorgan Chase & Co0.31990364917-693071-65.5084
2023-12-31Marshall Wace Asset Management Ltd0.28460.000432465800
2023-12-31Squarepoint Ops LLC0.250.0004285138222701356.6811
2023-12-31Two Sigma Investments LLC0.23190.0004264555230134668.586
Total 33.930.384338701708-2201146-5.7%

3.2. Funds holding Allovir Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Wasatch Ultra Growth2.04990.1336235470352822728.9206
2024-02-29Vanguard Total Stock Mkt Idx Inv1.54240.0001177172100
2024-03-28iShares Russell 2000 ETF1.14360.001513136296330.0482
2023-12-31Wasatch Micro Cap1.10330.1369126732646341057.6441
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.74750.000685861200
2024-01-31Fidelity Small Cap Index0.44590.001551223200
2024-03-28iShares Russell 2000 Value ETF0.41220.0029473496-300-0.0633
2024-02-29State St Russell Sm/Mid Cp® Indx NL Cl C0.29040.000633354900
2024-03-29Schwab US Small-Cap ETF™0.24860.001328562100
2024-02-29Fidelity Extended Market Index0.18420.0004211574-132191-38.4539
2024-02-29Vanguard Russell 2000 ETF0.16070.0014184591145968.5861
2024-01-31Fidelity VIP Disciplined Small Cap Init0.15630.0352179553136726319.2519
2024-02-29SPDR® Russell 2000 US Small Cap ETF0.14760.004716950686065.3487
2023-09-30BlackRock Extended Mkt Composite0.13890.00241595535584353.8453
2024-03-31State St Russell Sm Cap® Indx SL Cl I0.13450.001215447700
2023-12-31NT R2000 Value Index Fund - NL0.12060.0025138537-11261-7.5175
2024-03-31BlackRock Extended Equity Market K0.12010.0007137935500.0363
2023-12-31NT R2000 Index Fund - NL0.11970.0013137555-10986-7.3959
2024-02-29Schwab Small Cap Index0.10290.001511815000
2024-03-28iShares Micro-Cap ETF0.09470.008910880800
Total 9.4640.339210871128+1053353+9.7%

3.3. Insider Transactions

Insiders are holding 48.954% of the shares of Allovir Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-04-02Diana BrainardSELL15330.77
2024-04-02Brett R HagenSELL2810.77
2024-04-02Vikas SinhaSELL8850.77
2024-04-02Edward MillerSELL3680.77
2024-02-08Brett R HagenSELL111500.67
2024-02-05Brett R HagenSELL57920.67
2024-02-05Diana BrainardSELL414210.67
2024-02-05Edward MillerSELL88690.67
2024-02-05Vikas SinhaSELL183310.67
2024-01-23Brett R HagenSELL9010.67
2024-01-23Diana BrainardSELL95000.67
2024-01-23Edward MillerSELL13020.67
2024-01-23Vikas SinhaSELL32050.67
2024-01-04Brett R HagenSELL3100.64
2024-01-04Diana BrainardSELL16640.64
2024-01-04Edward MillerSELL4240.64
2024-01-04Vikas SinhaSELL9610.64
2023-11-20Diana BrainardSELL43821.69
2023-11-17Vikas SinhaSELL24901.63
2023-11-17Brett R HagenSELL4031.63

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Allovir Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.431-0.171-60%-0.002-100%0.071-712%0.071-712%
Book Value Per Share--1.2691.662-24%1.801-30%1.661-24%1.661-24%
Current Ratio--6.6157.512-12%10.592-38%12.612-48%12.612-48%
Debt To Asset Ratio--0.2360.211+12%0.177+33%0.292-19%0.292-19%
Debt To Equity Ratio--0.3090.269+15%0.216+43%0.155+100%0.155+100%
Dividend Per Share----0%-0%-0%-0%
Eps---0.520-0.414-20%-0.367-29%-0.296-43%-0.296-43%
Free Cash Flow Per Share---0.268-0.271+1%-0.309+15%-0.215-20%-0.215-20%
Free Cash Flow To Equity Per Share---0.267-0.117-56%-0.032-88%0.305-188%0.305-188%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---14.139--------
Intrinsic Value_10Y_min---12.129--------
Intrinsic Value_1Y_max---1.132--------
Intrinsic Value_1Y_min---1.111--------
Intrinsic Value_3Y_max---3.618--------
Intrinsic Value_3Y_min---3.449--------
Intrinsic Value_5Y_max---6.366--------
Intrinsic Value_5Y_min---5.890--------
Market Cap91895200.000+15%78110920.000292054432.500-73%679737307.500-89%1154561082.222-93%1154561082.222-93%
Net Profit Margin----0%-0%-0.8500%-0.8500%
Operating Margin----0%-0%-1.5350%-1.5350%
Operating Ratio----0%-0%0.989-100%0.989-100%
Pb Ratio0.630+15%0.5361.461-63%3.270-84%4.049-87%4.049-87%
Pe Ratio-0.385-18%-0.327-1.657+406%-4.044+1136%-8.838+2602%-8.838+2602%
Price Per Share0.800+15%0.6802.543-73%5.918-89%10.051-93%10.051-93%
Price To Free Cash Flow Ratio-0.747-18%-0.635-2.387+276%-4.795+655%-12.127+1809%-12.127+1809%
Price To Total Gains Ratio-1.854-18%-1.576-3.129+99%-11.859+652%-41.548+2536%-41.548+2536%
Quick Ratio--9.79910.279-5%15.835-38%18.230-46%18.230-46%
Return On Assets---0.313-0.203-35%-0.173-45%-0.134-57%-0.134-57%
Return On Equity---0.409-0.259-37%-0.212-48%-0.153-63%-0.153-63%
Total Gains Per Share---0.431-0.171-60%-0.002-100%0.071-712%0.071-712%
Usd Book Value--145781000.000190940000.000-24%206889250.000-30%190777888.889-24%190777888.889-24%
Usd Book Value Change Per Share---0.431-0.171-60%-0.002-100%0.071-712%0.071-712%
Usd Book Value Per Share--1.2691.662-24%1.801-30%1.661-24%1.661-24%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.520-0.414-20%-0.367-29%-0.296-43%-0.296-43%
Usd Free Cash Flow---30735000.000-31112750.000+1%-35487000.000+15%-24684333.333-20%-24684333.333-20%
Usd Free Cash Flow Per Share---0.268-0.271+1%-0.309+15%-0.215-20%-0.215-20%
Usd Free Cash Flow To Equity Per Share---0.267-0.117-56%-0.032-88%0.305-188%0.305-188%
Usd Market Cap91895200.000+15%78110920.000292054432.500-73%679737307.500-89%1154561082.222-93%1154561082.222-93%
Usd Price Per Share0.800+15%0.6802.543-73%5.918-89%10.051-93%10.051-93%
Usd Profit---59696000.000-47092500.000-21%-42125500.000-29%-33882500.000-43%-33882500.000-43%
Usd Revenue----0%-0%9166.667-100%9166.667-100%
Usd Total Gains Per Share---0.431-0.171-60%-0.002-100%0.071-712%0.071-712%
 EOD+5 -3MRQTTM+6 -23YOY+6 -235Y+5 -2610Y+5 -26

4.2. Fundamental Score

Let's check the fundamental score of Allovir Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.385
Price to Book Ratio (EOD)Between0-10.630
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than19.799
Current Ratio (MRQ)Greater than16.615
Debt to Asset Ratio (MRQ)Less than10.236
Debt to Equity Ratio (MRQ)Less than10.309
Return on Equity (MRQ)Greater than0.15-0.409
Return on Assets (MRQ)Greater than0.05-0.313
Total5/10 (50.0%)

4.3. Technical Score

Let's check the technical score of Allovir Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose0.780
Total0/1 (0.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Total Other Income Expense Net 1,8831652,048-1,5275212,1682,689-18,675-15,986



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets190,796
Total Liabilities45,015
Total Stockholder Equity145,781
 As reported
Total Liabilities 45,015
Total Stockholder Equity+ 145,781
Total Assets = 190,796

Assets

Total Assets190,796
Total Current Assets187,635
Long-term Assets3,161
Total Current Assets
Cash And Cash Equivalents 90,121
Short-term Investments 93,822
Net Receivables 206
Other Current Assets 3,486
Total Current Assets  (as reported)187,635
Total Current Assets  (calculated)187,635
+/-0
Long-term Assets
Property Plant Equipment 2,187
Long-term Assets Other 122
Long-term Assets  (as reported)3,161
Long-term Assets  (calculated)2,309
+/- 852

Liabilities & Shareholders' Equity

Total Current Liabilities28,367
Long-term Liabilities16,648
Total Stockholder Equity145,781
Total Current Liabilities
Short-term Debt 10,781
Accounts payable 6,761
Other Current Liabilities 10,825
Total Current Liabilities  (as reported)28,367
Total Current Liabilities  (calculated)28,367
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt16,648
Long-term Liabilities  (as reported)16,648
Long-term Liabilities  (calculated)16,648
+/-0
Total Stockholder Equity
Common Stock11
Retained Earnings -656,193
Accumulated Other Comprehensive Income -62
Other Stockholders Equity 802,025
Total Stockholder Equity (as reported)145,781
Total Stockholder Equity (calculated)145,781
+/-0
Other
Capital Stock11
Cash and Short Term Investments 183,943
Common Stock Shares Outstanding 113,967
Liabilities and Stockholders Equity 190,796
Net Debt -62,692
Net Invested Capital 145,781
Net Working Capital 159,268
Property Plant and Equipment Gross 4,105
Short Long Term Debt Total 27,429



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-31
> Total Assets 
0
0
0
139,422
128,690
117,846
393,710
370,821
351,281
327,511
316,530
286,594
231,090
199,995
293,698
277,079
244,044
282,692
248,312
190,796
190,796248,312282,692244,044277,079293,698199,995231,090286,594316,530327,511351,281370,821393,710117,846128,690139,422000
   > Total Current Assets 
0
0
0
127,313
117,351
107,288
383,941
361,317
339,664
316,045
281,872
253,348
206,441
176,517
272,042
243,052
212,275
252,912
220,019
187,635
187,635220,019252,912212,275243,052272,042176,517206,441253,348281,872316,045339,664361,317383,941107,288117,351127,313000
       Cash And Cash Equivalents 
0
0
0
61,084
64,380
78,267
142,250
122,661
168,645
225,447
243,187
201,661
100,206
71,093
123,834
106,092
115,698
196,954
95,627
90,121
90,12195,627196,954115,698106,092123,83471,093100,206201,661243,187225,447168,645122,661142,25078,26764,38061,084000
       Short-term Investments 
0
0
0
64,993
51,354
26,184
236,238
233,663
168,347
87,890
32,654
46,459
101,169
101,580
140,273
127,703
86,872
49,582
117,691
93,822
93,822117,69149,58286,872127,703140,273101,580101,16946,45932,65487,890168,347233,663236,23826,18451,35464,993000
       Net Receivables 
0
0
0
560
657
412
592
450
469
409
151
50
172
91
261
157
244
106
234
206
2062341062441572619117250151409469450592412657560000
       Other Current Assets 
0
0
0
676
960
2,837
5,453
4,993
2,203
2,299
5,880
5,178
4,894
3,753
7,674
7,100
9,705
4,737
6,701
3,486
3,4866,7014,7379,7057,1007,6743,7534,8945,1785,8802,2992,2034,9935,4532,837960676000
   > Long-term Assets 
0
0
0
12,109
11,339
10,558
9,769
9,504
11,617
11,466
34,658
33,246
24,649
23,478
21,656
34,027
31,769
29,780
28,293
3,161
3,16128,29329,78031,76934,02721,65623,47824,64933,24634,65811,46611,6179,5049,76910,55811,33912,109000
       Property Plant Equipment 
0
0
0
12,109
11,339
10,558
9,769
9,504
11,617
10,774
32,600
31,292
22,818
21,769
20,070
32,563
30,427
28,244
26,016
2,187
2,18726,01628,24430,42732,56320,07021,76922,81831,29232,60010,77411,6179,5049,76910,55811,33912,109000
       Other Assets 
0
0
0
0
0
10,558
0
9,504
11,617
692
2,058
33,246
1,831
23,478
21,656
1,464
0
29,780
0
0
0029,78001,46421,65623,4781,83133,2462,05869211,6179,504010,55800000
> Total Liabilities 
0
0
0
190,925
15,583
189,140
19,807
17,757
20,912
25,042
49,226
61,328
39,415
41,858
40,472
52,560
50,512
53,579
52,978
45,015
45,01552,97853,57950,51252,56040,47241,85839,41561,32849,22625,04220,91217,75719,807189,14015,583190,925000
   > Total Current Liabilities 
0
0
0
9,106
7,683
8,915
13,521
12,294
15,500
20,708
24,173
37,853
18,639
21,588
20,719
24,338
24,959
30,563
33,066
28,367
28,36733,06630,56324,95924,33820,71921,58818,63937,85324,17320,70815,50012,29413,5218,9157,6839,106000
       Short-term Debt 
0
0
0
3,067
3,107
3,147
3,188
3,229
4,785
4,830
6,297
6,591
2,356
2,238
1,918
7,165
8,270
8,483
12,976
10,781
10,78112,9768,4838,2707,1651,9182,2382,3566,5916,2974,8304,7853,2293,1883,1473,1073,067000
       Accounts payable 
0
0
0
630
1,812
680
1,843
963
2,057
4,202
133
8,361
4,473
5,518
4,889
3,004
4,134
5,164
3,925
6,761
6,7613,9255,1644,1343,0044,8895,5184,4738,3611334,2022,0579631,8436801,812630000
       Other Current Liabilities 
0
0
0
5,409
1
5,088
8,490
8,102
8,658
11,676
17,743
16,310
11,810
13,832
13,912
14,169
12,555
16,789
16,165
10,825
10,82516,16516,78912,55514,16913,91213,83211,81016,31017,74311,6768,6588,1028,4905,08815,409000
   > Long-term Liabilities 
0
0
0
181,819
7,900
180,225
6,286
5,463
5,412
4,334
25,053
23,475
20,776
20,270
19,753
28,222
25,553
23,016
19,912
16,648
16,64819,91223,01625,55328,22219,75320,27020,77623,47525,0534,3345,4125,4636,286180,2257,900181,819000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
20,270
0
0
0
0
0
0
00000020,2700000000000000
> Total Stockholder Equity
0
0
0
-51,503
113,107
-71,294
373,903
353,064
330,369
302,469
267,304
225,266
191,675
158,137
253,226
224,519
193,532
229,113
195,334
145,781
145,781195,334229,113193,532224,519253,226158,137191,675225,266267,304302,469330,369353,064373,903-71,294113,107-51,503000
   Common Stock
0
0
0
0
6
-71,294
7
7
7
7
7
7
7
7
9
9
9
11
11
11
11111199977777777-71,29460000
   Retained Earnings Total Equity00-552,225-506,958-465,775-427,639-385,567-340,928-297,065-239,124-193,614-156,026-125,1030000000
   Accumulated Other Comprehensive Income 
0
0
0
68
244
110
-41
-112
13
-25
-133
-155
-350
-444
-563
-468
-301
-225
-200
-62
-62-200-225-301-468-563-444-350-155-133-2513-112-4111024468000
   Capital Surplus 
0
0
0
0
0
0
0
478,272
486,375
496,101
506,554
522,479
532,946
544,141
681,419
690,753
700,782
781,552
0
0
00781,552700,782690,753681,419544,141532,946522,479506,554496,101486,375478,2720000000
   Treasury Stock00000000000000000000
   Other Stockholders Equity 
0
0
0
3,748
177,515
-168,241
80,131
478,272
486,375
496,101
506,554
522,479
532,946
544,141
681,419
690,753
700,782
781,552
792,020
802,025
802,025792,020781,552700,782690,753681,419544,141532,946522,479506,554496,101486,375478,27280,131-168,241177,5153,748000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-398
Gross Profit-398-398
 
Operating Income (+$)
Gross Profit-398
Operating Expense-180,933
Operating Income-181,331-181,331
 
Operating Expense (+$)
Research Development132,672
Selling General Administrative48,261
Selling And Marketing Expenses0
Operating Expense180,933180,933
 
Net Interest Income (+$)
Interest Income5,260
Interest Expense-0
Other Finance Cost-0
Net Interest Income5,260
 
Pretax Income (+$)
Operating Income-181,331
Net Interest Income5,260
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-190,544-172,118
EBIT - interestExpense = -181,331
-190,544
-190,418
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-181,331-190,544
Earnings Before Interest and Taxes (EBITDA)-180,933
 
After tax Income (+$)
Income Before Tax-190,544
Tax Provision--415
Net Income From Continuing Ops-168,858-190,129
Net Income-190,418
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses181,331
Total Other Income/Expenses Net-9,213-5,260
 

Technical Analysis of Allovir
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Allovir. The general trend of Allovir is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Allovir's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Allovir Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.85 < 1.31 < 1.34.

The bearish price targets are: 0.7057 > 0.67 > 0.6425.

Tweet this
Allovir Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Allovir Inc. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Allovir Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Allovir Inc.

Allovir Inc Daily Moving Average Convergence/Divergence (MACD) ChartAllovir Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Allovir Inc. The current adx is .

Allovir Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Allovir Inc.

Allovir Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Allovir Inc.

Allovir Inc Daily Relative Strength Index (RSI) ChartAllovir Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Allovir Inc.

Allovir Inc Daily Stochastic Oscillator ChartAllovir Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Allovir Inc.

Allovir Inc Daily Commodity Channel Index (CCI) ChartAllovir Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Allovir Inc.

Allovir Inc Daily Chande Momentum Oscillator (CMO) ChartAllovir Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Allovir Inc.

Allovir Inc Daily Williams %R ChartAllovir Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Allovir Inc.

Allovir Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Allovir Inc.

Allovir Inc Daily Average True Range (ATR) ChartAllovir Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Allovir Inc.

Allovir Inc Daily On-Balance Volume (OBV) ChartAllovir Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Allovir Inc.

Allovir Inc Daily Money Flow Index (MFI) ChartAllovir Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Allovir Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-07STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-08STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-11RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-14CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-28STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-09MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-17MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-26CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-30STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-21CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-22STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-01WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-15CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-18STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-19CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-21WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-01STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-11CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-04-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-18STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-22CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-24STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Allovir Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Allovir Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose0.780
Total0/1 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Allovir with someone you think should read this too:
  • Are you bullish or bearish on Allovir? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Allovir? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Allovir Inc

I send you an email if I find something interesting about Allovir Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Allovir Inc.

Receive notifications about Allovir Inc in your mailbox!